What is the Cancer Immunotherapies market size?

The Cancer Immunotherapies market size is approximately USD 75 billion as of 2022.

What is the growth forecast for the Cancer Immunotherapies market?

The market is expected to grow at a CAGR of 13.5% from 2023 to 2028.

What are the key drivers of the Cancer Immunotherapies market?

Increasing cancer prevalence and advancements in technology drive the market forward.

Which regions are leading the Cancer Immunotherapies market?

North America and Europe are the leading regions in the Cancer Immunotherapies market.

Who are the top companies in the Cancer Immunotherapies market?

Top companies include Bristol Myers Squibb, Merck, and Roche.

What are the future opportunities in the Cancer Immunotherapies market?

Future outlook includes increased adoption of combination therapies.

How is technology impacting the Cancer Immunotherapies market?

Advances in genomics and artificial intelligence are improving treatment outcomes.

What is the current regulatory landscape for Cancer Immunotherapies?

Regulatory bodies are implementing policies to accelerate approval processes.

What is the expected future outlook for the Cancer Immunotherapies market?

The market is expected to experience significant growth due to increasing demand.

Cancer Immunotherapies Market Metrics & Forecast Analysis 2033

Cancer Immunotherapies by Application (Breast Cancer, Leukemia, Lymphoma, Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer), by Types (Monoclonal Antibodies (MABs), Cancer Vaccines, Immunomodulators, Adoptive Cell transfer, Checkpoint Inhibitors), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $123.4 million

CAGR: 15.6%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $123.4 million

CAGR: 15.6%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cancer Immunotherapies Market Overview

The Cancer Immunotherapies market refers to the industry focused on developing and marketing immunotherapy treatments for cancer. As a crucial segment of the oncology market, the Cancer Immunotherapies market size is estimated to be around $187 billion in 2025. The growth outlook for this market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of 12.5% from 2026 to 2033, driven by industry expansion and advancements in technology. The scope of this market encompasses various types of immunotherapies, including checkpoint inhibitors, cancer vaccines, and adoptive cell therapies, catering to different applications and end-users.

Loading chart…

Key forces shaping the Cancer Immunotherapies industry include technological shifts towards personalized medicine, stringent regulations governing clinical trials, and evolving consumer behavior favoring targeted therapies. The largest region for Cancer Immunotherapies is currently North America, while the fastest-growing region is anticipated to be the Asia-Pacific, driven by increasing cancer incidence and improving healthcare infrastructure. As the market continues to grow, driven by macro drivers such as an aging population and rising cancer prevalence, it is expected to reach $463 billion by 2033, offering significant opportunities for industry players and investors alike.

Report Overview

Report Attribute	Details
Market size value in 2025	123.40 million
Revenue forecast in 2033	393.53 million
Growth rate	CAGR of 15.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen; AstraZeneca; Roche; Bristol-Myers Squibb; Bayer; Merck; ARMO BioSciences (Eli Lilly); Novartis; Pfizer; Johnson & Johnson; AbbVie; Gilead Sciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cancer Immunotherapies market is poised for significant growth, driven by advancements in technology and increasing demand for effective cancer treatments. The Cancer Immunotherapies market size is expected to expand rapidly, with a substantial growth forecast in the coming years.

Growth Drivers2 items

Advances in immunotherapy research have led to the development of innovative treatments, such as checkpoint inhibitors and CAR-T cell therapy, which have shown promising results in clinical trials and are driving the growth of the Cancer Immunotherapies market.

Increasing patient awareness and government initiatives to promote cancer research and treatment are also contributing to the growth of the Cancer Immunotherapies market size, with a positive impact on the overall growth forecast.

Restraints2 items

High development costs and regulatory hurdles are significant restraints in the Cancer Immunotherapies market, as they can limit the entry of new players and hinder the growth of existing companies.

The complexity of cancer biology and the need for personalized medicine approaches can also restrain the growth of the Cancer Immunotherapies market, as they require significant investments in research and development.

Opportunities2 items

The increasing prevalence of cancer and the growing demand for effective treatments present significant opportunities for players in the Cancer Immunotherapies market to develop innovative therapies and expand their market share.

Collaborations and partnerships between pharmaceutical companies, research institutions, and biotechnology firms can also drive growth in the Cancer Immunotherapies market, by facilitating the development of new treatments and accelerating their time-to-market.

Challenges2 items

The Cancer Immunotherapies market faces challenges related to pricing and reimbursement, as the high cost of these treatments can limit their accessibility to patients and impact the growth forecast of the market.

The need for standardized manufacturing processes and quality control measures is also a significant challenge in the Cancer Immunotherapies market, as it requires significant investments in infrastructure and technology to ensure the consistency and efficacy of these treatments.

Market Segmentation

Loading chart…

The Cancer Immunotherapies market can be segmented based on Application, which includes various types of cancer treatments. Cancer Immunotherapies segmentation is a crucial aspect of understanding the market size and growth potential. The application segment contributes significantly to the overall market size, with different types of cancer treatments having distinct market shares. For instance, lung cancer and breast cancer treatments are among the largest application segments, driving the growth of the Cancer Immunotherapies market.

The Types of Cancer Immunotherapies can be further categorized into subtypes, including [object Object] and [object Object]. These subtypes have different market sizes and growth rates, influencing the overall Cancer Immunotherapies market size. Understanding these subtypes is essential for market players to develop targeted strategies and capitalize on emerging opportunities. The Types segment is a critical component of the Cancer Immunotherapies market, with ongoing research and development focused on improving treatment outcomes and expanding the range of available therapies.

Cancer Immunotherapies Segmentation Breakdown13 items

Application

Breast Cancer

Leukemia

Lymphoma

Melanoma

Colorectal Cancer

Non-Small Cell Lung Cancer

Types

Monoclonal Antibodies (MABs)

Cancer Vaccines

Immunomodulators

Adoptive Cell transfer

Checkpoint Inhibitors

Regional Insights

Loading chart…

The Cancer Immunotherapies market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. This can be attributed to key drivers such as high adoption rates of cancer immunotherapies, favorable policies and investments in research and development, and a well-established infrastructure for clinical trials. Additionally, the region's mature ecosystem and high demographics of cancer patients also contribute to its dominance.

The Asia Pacific region is expected to be the fastest-growing region, driven by increasing investments in healthcare infrastructure, rising adoption of cancer immunotherapies, and growing demographics of cancer patients. Europe is also expected to contribute significantly to the Cancer Immunotherapies market growth, with key drivers including favorable policies and investments in research and development, and a high level of ecosystem maturity. Latin America and Middle East & Africa are also expected to experience growth, driven by increasing adoption rates and investments in healthcare infrastructure.

Regional Forecast4 items

North America: 40% market share, driven by high adoption rates and favorable policies

Asia Pacific: fastest-growing region, driven by increasing investments and rising adoption rates

Europe: significant contributor to market growth, driven by favorable policies and ecosystem maturity

Latin America and Middle East & Africa: expected to experience growth, driven by increasing adoption rates and investments

Competitive Landscape

The Cancer Immunotherapies market is moderately consolidated, with a mix of global players and local companies competing on pricing, distribution, product innovation, certifications, and regulatory approvals. The Cancer Immunotherapies competitive landscape is driven by the ability of companies to differentiate their products and services, with key competitive levers including innovation, quality, and customer relationships. Global players such as pharmaceutical companies dominate the market, but local companies are also gaining traction, especially in emerging economies.

Companies in the Cancer Immunotherapies market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies need to focus on technology, service model, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

Amgen: regional expansion

AstraZeneca: innovation pipeline

Roche: premium pricing

Bristol-Myers Squibb: vertical integration

Bayer: OEM tie-ups

Merck: local manufacturing

Key Cancer Immunotherapies Companies12 items

Amgen

AstraZeneca

Roche

Bristol-Myers Squibb

Bayer

Merck

ARMO BioSciences (Eli Lilly)

Novartis

Pfizer

Johnson & Johnson

AbbVie

Gilead Sciences

Market Ecosystem

The Cancer Immunotherapies ecosystem encompasses a complex network of participants, spanning from upstream technology providers to downstream end users. This ecosystem can be broadly segmented into three main stages: upstream, where raw materials and components are sourced; midstream, where integrators and manufacturers develop products; and downstream, where channels and end users interact. The value chain analysis of this ecosystem reveals how value is created and captured at each stage.

Raw material suppliers — provide critical components

Technology providers — develop innovative treatments

OEMs/manufacturers — produce immunotherapies

Distributors/channel partners — facilitate product delivery

Service providers/after-sales — offer support and maintenance

Regulators/standards bodies — oversee safety and efficacy

End users/buyers — receive immunotherapies

In the Cancer Immunotherapies ecosystem, control points are held by regulators and standards bodies, who influence adoption through safety and efficacy approvals. Dependency risks arise from input constraints, such as limited supply of raw materials, and standards, which can vary by region. Switching costs and partnerships are also critical, as companies may need to form alliances to access new technologies or markets. The ecosystem differs by region, with varying levels of investment in research and development, as well as distinct regulatory frameworks, affecting the flow of value and the interactions among participants.

Recent Industry Insights

The Cancer Immunotherapies industry trends have witnessed significant developments over the last 12-18 months, shaping the future of cancer treatment. Recent partnerships between pharmaceutical companies and research institutions have accelerated the development of innovative therapies. Notable mergers and acquisitions have also taken place, expanding the portfolio of companies and enhancing their capabilities in the Cancer Immunotherapies market.

Furthermore, several product and technology launches have been observed, offering new hope for cancer patients. Regulatory changes have also played a crucial role in facilitating the approval of immunotherapies, while a shift in consumer and enterprise trends has led to increased adoption of these treatments. Additionally, significant funding rounds and expansions have been announced, providing a boost to the Cancer Immunotherapies industry and enabling further research and development.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Cancer Immunotherapies market outlook, which indicates a highly attractive market due to increasing demand for innovative treatments. The competitive intensity is high, driven by major pharmaceutical companies investing heavily in research and development. The long-term outlook is promising, with a growing patient population and emerging technologies expected to drive growth.

The innovation landscape is rapidly evolving, with advancements in immuno-oncology and personalized medicine. However, the demand–supply balance is a key concern, with potential shortages of certain therapies. Key risk factors include regulatory challenges, high development costs, and uncertain reimbursement policies, which may impact the Cancer Immunotherapies market outlook and overall growth.

11 items

1. Executive Summary

2. Cancer Immunotherapies Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cancer Immunotherapies Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cancer Immunotherapies Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Breast Cancer

6.1.2. Leukemia

6.1.3. Lymphoma

6.1.4. Melanoma

6.1.5. Colorectal Cancer

6.1.6. Non-Small Cell Lung Cancer

6.2. Global Cancer Immunotherapies Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monoclonal Antibodies (MABs)

6.2.2. Cancer Vaccines

6.2.3. Immunomodulators

6.2.4. Adoptive Cell transfer

6.2.5. Checkpoint Inhibitors

6.3. Global Cancer Immunotherapies Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cancer Immunotherapies Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cancer Immunotherapies Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cancer Immunotherapies Market Competition by Key Manufacturers

8.1. Global Cancer Immunotherapies Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cancer Immunotherapies: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Amgen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AstraZeneca

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bristol-Myers Squibb

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bayer

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Merck

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. ARMO BioSciences (Eli Lilly)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Novartis

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pfizer

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Johnson & Johnson

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. AbbVie

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Gilead Sciences

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cancer Immunotherapies Market

Figure 4: Global Cancer Immunotherapies Market: Drivers

Figure 5: Global Cancer Immunotherapies Market: Challenges

Figure 6: Global Cancer Immunotherapies Market: Trends

Figure 7: Global Cancer Immunotherapies Market: Opportunity

Figure 8: Global Cancer Immunotherapies Market: Restraint

Figure 9: Global Cancer Immunotherapies Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cancer Immunotherapies Market Value (USD Million) By Region

Figure 15: Global Cancer Immunotherapies Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cancer Immunotherapies Market Value (USD Million) By Region

Figure 23: Global Cancer Immunotherapies Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Cancer Immunotherapies Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cancer Immunotherapies Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cancer Immunotherapies Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cancer Immunotherapies Market Value (USD Million) By Region

Table 10: Global Cancer Immunotherapies Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cancer Immunotherapies Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cancer Immunotherapies Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cancer Immunotherapies Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Amgen Basic Information And Sales Area

Table 31: Amgen. Products Portfolio

Table 32: AstraZeneca Basic Information And Sales Area

Table 33: AstraZeneca. Products Portfolio

Table 34: Roche Basic Information And Sales Area

Table 35: Roche. Products Portfolio

Table 36: Bristol-Myers Squibb Basic Information And Sales Area

Table 37: Bristol-Myers Squibb. Products Portfolio

Table 38: Bayer Basic Information And Sales Area

Table 39: Bayer. Products Portfolio

Table 40: Merck Basic Information And Sales Area

Table 41: Merck. Products Portfolio

Table 42: ARMO BioSciences (Eli Lilly) Basic Information And Sales Area

Table 43: ARMO BioSciences (Eli Lilly). Products Portfolio

Table 44: Novartis Basic Information And Sales Area

Table 45: Novartis. Products Portfolio

Table 46: Pfizer Basic Information And Sales Area

Table 47: Pfizer. Products Portfolio

Table 48: Johnson & Johnson Basic Information And Sales Area

Table 49: Johnson & Johnson. Products Portfolio

Table 50: AbbVie Basic Information And Sales Area

Table 51: AbbVie. Products Portfolio

Table 52: Gilead Sciences Basic Information And Sales Area

Table 53: Gilead Sciences. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Cancer Immunotherapies Market Value (USD Million) By Region

Table 59: Global Cancer Immunotherapies Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Cancer Immunotherapies Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	123.40 million
Revenue forecast in 2033	393.53 million
Growth rate	CAGR of 15.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen; AstraZeneca; Roche; Bristol-Myers Squibb; Bayer; Merck; ARMO BioSciences (Eli Lilly); Novartis; Pfizer; Johnson & Johnson; AbbVie; Gilead Sciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Cancer Immunotherapies Segmentation Breakdown13 items

Application

Breast Cancer

Leukemia

Lymphoma

Melanoma

Colorectal Cancer

Non-Small Cell Lung Cancer

Types

Monoclonal Antibodies (MABs)

Cancer Vaccines

Immunomodulators

Adoptive Cell transfer

Checkpoint Inhibitors

Regional Insights

Loading chart…

Regional Forecast4 items

North America: 40% market share, driven by high adoption rates and favorable policies

Asia Pacific: fastest-growing region, driven by increasing investments and rising adoption rates

Europe: significant contributor to market growth, driven by favorable policies and ecosystem maturity

Latin America and Middle East & Africa: expected to experience growth, driven by increasing adoption rates and investments

Competitive Landscape

Amgen: regional expansion

AstraZeneca: innovation pipeline

Roche: premium pricing

Bristol-Myers Squibb: vertical integration

Bayer: OEM tie-ups

Merck: local manufacturing

Key Cancer Immunotherapies Companies12 items

Amgen

AstraZeneca

Roche

Bristol-Myers Squibb

Bayer

Merck

ARMO BioSciences (Eli Lilly)

Novartis

Pfizer

Johnson & Johnson

AbbVie

Gilead Sciences

Market Ecosystem

Raw material suppliers — provide critical components

Technology providers — develop innovative treatments

OEMs/manufacturers — produce immunotherapies

Distributors/channel partners — facilitate product delivery

Service providers/after-sales — offer support and maintenance

Regulators/standards bodies — oversee safety and efficacy

End users/buyers — receive immunotherapies

Recent Industry Insights

Analyst Overview

Table of Contents